| Carri Jo Timmer, DO | |
|
11225 Pacific Avenue, Parkland Clinic, Tacoma, WA 98444 | |
| (253) 536-2020 | |
| (253) 536-5327 |
| Full Name | Carri Jo Timmer |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 11225 Pacific Avenue, Tacoma, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033344791 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OP60221510 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Health Care | 1850201559 | 75 |
News Archive
Clinical guidelines for the treatment of depression and anxiety problems recommend evidence-based psychological interventions organized in a stepped care model, where patients initially access low-intensity self-help interventions guided by qualified practitioners and later have the option to access high-intensity psychological therapies if their symptoms persist.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
Researchers at the University of Pennsylvania School of Medicine, in collaboration with scientists at the City University of New York, have identified a striking dysregulation in neuronal receptor activity in the postmortem brain tissue from patients with schizophrenia.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
The trade group for pharmaceutical companies, PhRMA, has filed another lawsuit to try to block a government rule meant to widen the number of products included in a federal drug discount program for so-called safety net hospitals and clinics.
› Verified 6 days ago
| Entity Name | Community Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790762755 PECOS PAC ID: 1850201559 Enrollment ID: O20040213000045 |
News Archive
Clinical guidelines for the treatment of depression and anxiety problems recommend evidence-based psychological interventions organized in a stepped care model, where patients initially access low-intensity self-help interventions guided by qualified practitioners and later have the option to access high-intensity psychological therapies if their symptoms persist.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
Researchers at the University of Pennsylvania School of Medicine, in collaboration with scientists at the City University of New York, have identified a striking dysregulation in neuronal receptor activity in the postmortem brain tissue from patients with schizophrenia.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
The trade group for pharmaceutical companies, PhRMA, has filed another lawsuit to try to block a government rule meant to widen the number of products included in a federal drug discount program for so-called safety net hospitals and clinics.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carri Jo Timmer, DO 1019 Pacific Ave Ste 300, Attn: Credentialing, Tacoma, WA 98402-4488 Ph: (253) 722-1540 | Carri Jo Timmer, DO 11225 Pacific Avenue, Parkland Clinic, Tacoma, WA 98444 Ph: (253) 536-2020 |
News Archive
Clinical guidelines for the treatment of depression and anxiety problems recommend evidence-based psychological interventions organized in a stepped care model, where patients initially access low-intensity self-help interventions guided by qualified practitioners and later have the option to access high-intensity psychological therapies if their symptoms persist.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
Researchers at the University of Pennsylvania School of Medicine, in collaboration with scientists at the City University of New York, have identified a striking dysregulation in neuronal receptor activity in the postmortem brain tissue from patients with schizophrenia.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
The trade group for pharmaceutical companies, PhRMA, has filed another lawsuit to try to block a government rule meant to widen the number of products included in a federal drug discount program for so-called safety net hospitals and clinics.
› Verified 6 days ago
Dr. Kristina Siu Petsas, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 | |
Mrs. Anne Garces Laporte, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 | |
Dr. Charles Gilbert Childers, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 2624 S 38th St, Tacoma, WA 98409 Phone: 253-475-5908 Fax: 253-475-5958 | |
James M Roos, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-403-1000 | |
Loren B Betteridge, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3733 S Thompson Ave, Tacoma, WA 98418 Phone: 253-472-4473 Fax: 253-474-3056 | |
Dr. Thuy-tien V Le, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 732 Broadway Ste 201, Tacoma, WA 98402 Phone: 702-871-8535 Fax: 941-499-0035 | |
Alexander K Lee, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-459-7785 |